Noah AI closes Pre-A+ round co-led by Yijing Capital and HSG

Recently, Noah AI, an automated AI-powered pharmaceutical R&D company, has successfully completed a Pre-A+ round of financing with oversubscription. This round was co-led by Yijing Capital and HSG (formerly known as Sequoia Capital China), with participation from a fund under CICC Capital and Sinovation Ventures.It is reported that the funds raised will be primarily used for talent recruitment, product iteration, and commercial expansion.

Noah AI was founded in November 2023 and focuses on building AI Agents capable of thinking and executing tasks like pharmaceutical industry experts.

The Noah platform aggregates data from tens of thousands of global medical and professional data sources, covering the entire drug lifecycle from early-stage R&D and clinical development to commercialization and market access. Based on Noah's proprietary data pipeline, it provides a high-quality data foundation for AI Agents to perform professional tasks. Furthermore, the Noah platform, leveraging the team's extensive experience in the pharmaceutical sector and expert Chain-of-Thought data extracted from high-quality industry papers and reports, enhances the AI Agent's capabilities in pharmaceutical task planning, data retrieval, and tool utilization. This enables the AI Agents to think and execute like pharmaceutical experts and deliver high-quality outputs.

Currently, Noah AI serves over 10,000 users worldwide and maintains deep collaborations with several multinational pharmaceutical companies and leading domestic Chinese pharmaceutical companies. Its solutions have achieved scaled implementation across multiple scenarios, including drug target evaluation, pipeline strategy, market analysis, clinical protocol writing, competitive intelligence analysis, partner identification for licensing deals, and medical writing.